A Busy 2019 ends with a quiet December

January 10, 2020
-

pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations.  Highlights since the last update include:

  • 3 products completed CADTH review, for a total of 10 files under consideration;
  • 0 products initiated pCPA negotiations, for a total of 32 active negotiations;
  • 1 negotiation completed for a total of 295 completed negotiations;
  • 1 negotiation closed, for a total of 48 closed negotiations; and
  • 1 file closed without negotiations, for a total of 73 declined negotiations.

  

Files Under pCPA Consideration

 

3 new drug products received a CDEC recommendation or pERC notification to implement in December 2019, for a total of approximately 10 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Tegsedi* Inotersen Akcea Therapeutics Hereditary Transthyretin Amyloidosis Conditional
Lynparza Olaparib AstraZeneca Ovarian Cancer Conditional
Nerlynx Neratinib Knight Therapeutics Hormone Receptor Positive Breast Cancer
Does not recommend

*While this file received a CADTH recommendation in December, Tegsedi commenced negotiations in November 2019 following an August 2019 INESSS recommendation and therefore, has not been counted as an under-consideration file.

 

Signals Decoded:
 
Lynparza, which is already widely reimbursed as a maintenance treatment option in ovarian cancer, receives a conditional recommendation for use in newly diagnosed ovarian cancer. Tegsedi, which had negotiations initiated in November 2019, receives a conditional recommendation from CADTH.

 

 

Completed

 

The pCPA completed 1 negotiation since the last update for a total of 295 completed negotiations.

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Prevymis Letermovir Merck Prevention of Cytomegalovirus Infection Nov 2018 395 days

 

Closed

The pCPA closed 1 negotiation since the last update for a total of 48 closed negotiations.

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Lutathera Lutetium Lu-177 Advanced Accelerator Applications Midgut Neuroendocrine Tumours Sep 2019 91 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

Signals Decoded:

Of the 32 active negotiations, the 18 non-oncology files have been under active negotiation for an average of 235 calendar days as of December 15, 2019 (range: 30 to 944 days). The remaining 14 oncology files have been under active negotiation for an average of 201 calendar days as of December 15, 2019. (range: 30 to 487 days).

 

 

Not Negotiated

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Decision*
Vitrakvi Larotrectinib Bayer Locally Advanced or Metastatic Solid Tumors that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion 15 Nov 19 30 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
css.php